Compare Cassava Sciences Inc (FLNA) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Phillips 66 — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Phillips 66 trades at $201.33 (market cap $78.65B). The key difference: Phillips 66 is far larger — about 1480.1× Cassava Sciences Inc's market cap, and Phillips 66 pays a 2.59% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PSX | |
|---|---|---|
Market Cap | $53.14M | $78.65B |
Sector | Health | Energy |
52-Week High | $4.64 | $201.45 |
52-Week Low | $1.09 | $118.37 |
Enterprise Value | -$33.43M | $100.62B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Phillips 66 (PSX) trades at $201.86, up 0.2% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, including Q1 2026's surprise profit, while maintaining solid profitability metrics like a 14.75% ROE. Recent news highlights refining margin strength and dividend consistency, with two $1.27 payouts in 2026. Cash flow trends improved in 2025, though revenue has declined from 2022 peaks.
PSX offers value with a P/E of 19.38 and P/S of 0.59, supported by 57% analyst buy ratings and a $201.50 consensus target. Risks include volatile refining margins, debt levels at 27.18% of assets, and revenue contraction since 2022. The stock's proximity to its 52-week high suggests limited near-term upside without new catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
